• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Oncology division













Was called about an Onc opportunity with Eisai. Told bonus target was 48 and opportunity to double it at year end with annual bonus. Why would reps be looking to leave that kind of payout?
 








Just resigned- better company, better management, growing in oncology, has a future. Just received a new indication. Eisai oncology may not be around long so I felt I needed to leave.
 
















































Six months in and yes, the oncology division is a mess. As big pharma primary care I have experienced since my primary care days 20 years ago. Will be out of here in the new year.